Trillium Health Care Products Inc.

Trillium Health Care Products Inc. functions as a contract manufacturer specializing in the formulation of prescription and over-the-counter life science-based products, focusing on the North American market. Trillium Health Care Products Inc. was founded in 1998 in Brockville, Canada.

The company specializes in contract manufacturing for pharmaceutical and healthcare sectors. Joe Ruffo serves as the CEO. In August 2024, Avista Capital Partners acquired Trillium from New Water Capital. Financial terms were not disclosed.

The company has participated in 4 deals with the most recent deal occurring on 2024-08-07. Trillium Health Care Products Inc. specializes in the formulation and contract manufacturing of prescription (RX) and over-the-counter (OTC) life science-based products, primarily targeting the North American market, which includes both the United States and Canada. The company's core product offerings encompass a variety of health-related remedies, including gastrointestinal treatments, cough, cold & flu medications, antiseptic ointments, nasal sprays, allergy relief agents, analgesics, sleep aids, and other prescription drugs.

These products are designed to address various consumer health needs, ensuring safety and efficacy for end users, which includes both individual consumers and healthcare providers. Trillium serves a diverse client base comprised of leading pharmaceutical and consumer healthcare companies, emphasizing confidentiality and adherence to rigorous manufacturing standards to maintain high-quality standards. Trillium Health Care Products operates on a B2B model, generating revenue primarily through partnerships with pharmaceutical and consumer healthcare companies. The company engages in contract manufacturing agreements, where clients outsource their product development and manufacturing needs to Trillium.

This business structure allows for tailored solutions that meet specific client requirements, fostering long-term relationships with its partners. Pricing structures are established based on customer contracts, which outline production volumes and timelines, ensuring mutual profitability. While specific details regarding individual product pricing or revenue figures are proprietary, the extensive experience and strategic position of Trillium in the North American market underscore its capability to deliver high-quality healthcare products and maintain robust revenue streams. In August 2024, the acquisition by Avista Capital Partners is expected to facilitate Trillium's expansion in business development and strengthen its market presence within the healthcare sector.

The company aims to introduce new products and enhance its operational capabilities, although specific launch dates are not detailed at this time. The acquisition will also support Trillium's efforts to penetrate new geographic markets, strategically targeting broader North American regions. Recent funding from the acquisition will be utilized to bolster these initiatives, ultimately enhancing Trillium's footprint within the healthcare landscape.